Cervix Cancer

A Phase II Evaluation of ABI-007 (IND#55,974) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (Abraxis BioScience, Inc. Study #CA026)  [GOG 0127V] Temporarily closed to accrual

Principal Investigator:
S. K. Sharma, M.D,
Adventist Hinsdale Hospital
(630) 856-6757
Contact: Peg Gregus, RN, MSN

A Phase III Randomized Trial of Weekly Cisplatin and Radiation versus Cisplatin and Tirapazamine and Radiation in Stage IB2, IIA, IIB, IIIB, and IVA Cervical Carcinoma Limited to the Pelvis [GOG 0219]

Principal Investigator:
S. K. Sharma, M.D,
Adventist Hinsdale Hospital
(630) 856-6757
Contact: Peg Gregus, RN, MSN

Prospective Evaluation of Pelvic Exenteration in Patients with Recurrent Cervical Cancer [GOG 0222]

Principal Investigator:
S. K. Sharma, M.D,
Adventist Hinsdale Hospital
(630) 856-6757
Contact: Peg Gregus, RN, MSN

A Phase II Evaluation of Cetuximab (Erbitux®, C225, NSC# 714692) in the Treatment of Persistent or Recurrent Squamous or Non-Squamous Cell Carcinoma of the Cervix [GOG 0227E] Temporarily closed to accrual.

Principal Investigator:
S. K. Sharma, M.D,
Adventist Hinsdale Hospital
(630) 856-6757
Contact: Peg Gregus, RN, MSN